Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Incyte Corporation's results were a major disappointment as it failed to meet the revenue expectations as well as the earnings expectations of Wall Street.</li><li>In the third quarter, Incyte sustained robust double-digit revenue growth, achieving noteworthy pricing, reimbursement, and pipeline advancement milestones.</li><li>The quarter's product and royalty revenues reached $914 million, reflecting an 11% year-over-year growth propelled by Jakafi and Opzelura.</li></ul>

Incyte Corporation's results were a major disappointment as it failed to meet the revenue expectations as well as the earnings expectations of Wall Street.In the third quarter, Incyte sustained robust double-digit revenue growth, achieving noteworthy pricing, reimbursement, and pipeline advancement milestones.The quarter's product and royalty revenues reached $914 million, reflecting an 11% year-over-year growth propelled by Jakafi and Opzelura.

Incyte Corporation: Competitive Landscape and Market Positioning of Jakafi! - Major Drivers

<ul><li>Incyte Corporation delivered an all-around beat in the previous quarter.</li><li>With patient demand for all indications rising, net product revenues for the quarter increased.</li><li>The quarter also saw a rise in US patient demand, as total prescriptions grew over the previous quarter, and refills increased.</li></ul>

Incyte Corporation delivered an all-around beat in the previous quarter.With patient demand for all indications rising, net product revenues for the quarter increased.The quarter also saw a rise in US patient demand, as total prescriptions grew over the previous quarter, and refills increased.

Incyte Corporation: 4 Proven Strategies Driving The Recent Financial Performance - Financial Forecasts

Equity Capital Markets

<ul><li>Incyte had a terribly disappointing first quarter and failed to meet the revenue expectations as well as earnings expectations of Wall Street.</li><li>The company’s product revenue increased 14% year over year as Jakafi was in high demand among patients across all indications.</li><li>In hematology and oncology, the ongoing launches of Pemazyre and Minjuvi ex-U.S. were the primary factors in the 17% rise year over year.</li></ul>

Incyte had a terribly disappointing first quarter and failed to meet the revenue expectations as well as earnings expectations of Wall Street.The company’s product revenue increased 14% year over year as Jakafi was in high demand among patients across all indications.In hematology and oncology, the ongoing launches of Pemazyre and Minjuvi ex-U.S. were the primary factors in the 17% rise year over year.

Incyte Corporation: New Approvals for Opzelura and Zynyz & Other Drivers

<ul><li>Incyte Corporation generated strong financial performance in the last quarter and managed an all-around beat.</li><li>Revenues from the commercialized items in the company's current portfolio increased by 18% year over year.</li><li>We give Incyte Corporation a 'Hold' rating with a revised target price.</li></ul>

Incyte Corporation generated strong financial performance in the last quarter and managed an all-around beat.Revenues from the commercialized items in the company's current portfolio increased by 18% year over year.We give Incyte Corporation a 'Hold' rating with a revised target price.

Incyte Corporation: Continued Diversification In Derma & Oncology – Key Drivers

Global Healthcare Analyst

Tina Banerjee

Event-Driven

Sun Pharmaceutical Industries / Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sun-pharmaceutical-industries-limited" target="_blank" data-smartkarma-citation="entities:98:1" rel="noopener">Sun Pharmaceutical Industries (SUNP IN)</a> is acquiring the U.S.-based late-stage biotechnology company, <a href="https://www.smartkarma.com/entities/concert-pharmaceuticals-inc" target="_blank" data-smartkarma-citation="entities:9312:1" rel="noopener">Concert Pharmaceuticals (CNCE US)</a> for $576M in equity value. The transaction is expected to be completed in 1Q23.</li>
<li>Concert has completed the evaluation of the efficacy and safety of its lead candidate, deuruxolitinib in adult patients with moderate to severe Alopecia Areata in its phase 3 clinical program.</li>
<li>With the disease affecting up to ~1.5M people in the U.S., Alopecia represents potential blockbuster opportunity. Sun Pharma plans to file NDA for deuruxolitinib to the FDA in 1H23.</li>
</ul>



Sun Pharmaceutical Industries (SUNP IN) is acquiring the U.S.-based late-stage biotechnology company, Concert Pharmaceuticals (CNCE US) for $576M in equity value. The transaction is expected to be completed in 1Q23.
Concert has completed the evaluation of the efficacy and safety of its lead candidate, deuruxolitinib in adult patients with moderate to severe Alopecia Areata in its phase 3 clinical program.
With the disease affecting up to ~1.5M people in the U.S., Alopecia represents potential blockbuster opportunity. Sun Pharma plans to file NDA for deuruxolitinib to the FDA in 1H23.


Sun Pharmaceutical Ind (SUNP IN): Acquisition Adds Late-Stage Biopharma Product in Derma Franchise

United States

Incyte Corp is a biopharmaceutical company. The Company discovers, develops and commercializes proprietary small molecule drugs, primarily used in oncology.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Incyte Corp (INCY US)

Incyte Corporation: Competitive Landscape and Market Positioning of Jakafi! - Major Drivers

Incyte Corporation's results were a major disappointment as it failed to meet the revenue expectations as well as the earnings expectations of...

Baptista Research

Incyte Corporation: 4 Proven Strategies Driving The Recent Financial Performance - Financial Forecasts

Incyte Corporation delivered an all-around beat in the previous quarter. With patient demand for all indications rising, net product revenues for...

Baptista Research

Incyte Corporation: New Approvals for Opzelura and Zynyz & Other Drivers

Incyte had a terribly disappointing first quarter and failed to meet the revenue expectations as well as earnings expectations of Wall Street. The...

Baptista Research

Incyte Corporation: Continued Diversification In Derma & Oncology – Key Drivers

Incyte Corporation generated strong financial performance in the last quarter and managed an all-around beat. Revenues from the commercialized...

Baptista Research

Sun Pharmaceutical Ind (SUNP IN): Acquisition Adds Late-Stage Biopharma Product in Derma Franchise

Sun Pharma is acquiring US-based Concert Pharmaceuticals for $576M. Post-acquisition, the priority will be to materialize Concert’s plan to submit...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)